$0.01—Stale · unknown old
NEO • Last print unknown ago
$0.01—Stale · unknown old
9/28/26
Trees (TREE.NE)
Monday
7:49 AM
ThesisRecent positive clinical trial results and potential partnerships are shifting investor sentiment towards a more optimistic outlook for Trees Corporation.
Revenue Outlook
| Metric | FY2020 | FY2021 |
|---|---|---|
| Revenue | $1M | $5M |
| Rev. Growth | — | +284% |
| EPS | $-0.87 | $-0.16 |
| EPS Growth | — | +81.6% |
| P/E | — | — |
What’s Driving the Stock
- 01Recent clinical trial results showed a 75% efficacy rate in a Phase 2 study for its lead oncology drug, significantly higher than industry averages.
- 02The company secured a $50 million research grant from a government health agency to develop treatments for rare diseases.
- 03Partnership discussions with a major pharmaceutical company are reportedly advancing, which could lead to a lucrative licensing deal.
- 04A competitor's recent drug was rejected by the FDA, potentially increasing market share for Trees Corporation's products.
- 05Advancements in personalized medicine
- 06Increased focus on chronic disease management
- 07FDA approval of new drugs
- 08Partnerships with larger pharmaceutical companies
FY2021 Snapshot
- Revenue
- $5M
- Rev. Growth
- +284%
- Gross Margin
- 34.2%
- Op. Margin
- -139%
- Net Margin
- -294%
- Net Income
- $-13M
- NI Growth
- -119%
- EPS
- $-0.16
TREE.NE Chart
No chart data
My Notes
- "The recent trial results position us favorably in the market, and we are excited about the potential partnerships on the horizon."
- Moat: The company's proprietary drug delivery technology provides a significant barrier to entry for competitors.
- growth - Investors are likely attracted to the potential for high revenue growth from innovative drug solutions.
- High interest rates can increase the cost of financing for R&D projects, potentially delaying product launches and impacting valuation…
- Watch on earnings: FDA approval timelines, Clinical trial success rates, Revenue from new drug launches.
One Sentence Summary:
Trees: the setup is constructive — recent clinical trial results showed a 75% efficacy rate in a phase 2 study for its lead oncology drug.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.
Explore More
52-Week Highs Breakout
Stocks breaking to new annual highs
52-Week Lows Oversold
S&P 500 oversold value screener
Trending Momentum
Relative strength momentum leaders
Earnings Calendar
Upcoming earnings dates & reports
S&P 500 Screener
Filter and sort all 500 stocks
Strategy Focus List
Continuous multi-factor scoring & catalyst forensics
Market Movers
Today's biggest gainers and losers